The EU pays more than 1 billion euros for Remdesivir October 13, 2020September 21, 2022 Coronaheadsup.com Coronavirus, Europe, Health, Remdesivir, Treatment The European Union has agreed to pay more than 1 billion euros to Gilead for a six-month supply of its antiviral drug remdesivir, shortly before the publication of final results of the biggest trial of the COVID-19 medication. Reuters report ** This post was originally published on October 13, 2020 **Share this:Tweet Related Posts: Research: 14.6% Paxlovid contraindication rate for hospitalized patients with Covid-19COVID-19 reinfections increase risk of organ failure, deathPreprint: Neutralizing antibodies in deer for at least 13 months for 90% of animalsLancet: Protection from previous natural infection compared with mRNA vaccinationCanada: First evidence of deer-to-human transmissionUganda closes schools after eight children die of Ebola
